Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Cancer Discov. 2019 Jul 2;9(9):1288–1305. doi: 10.1158/2159-8290.CD-19-0161

Figure 2. iαβTs infiltrating PDA are phenotypically distinct.

Figure 2.

WT mice bearing orthotopic KPC tumors were sacrificed on day 21. (a-g) Splenic and PDA-infiltrating iαβTs were tested for expression of (a) JAML, (b) CD107a, (c) CTLA-4, (d) TIM-3, (e) PD-1, (f) CD39, (g) CD40L, LAG-3, CD73, ICOS, and Dectin-1. (h) Splenic and PDA-infiltrating iαβTs were tested for expression of CD62L. (i) TCR sequencing of splenic iαβTs and PDA-infiltrating iαβTs, CD4+ and CD8+ T cells was performed in triplicate and assessed for overlapping clones between populations. (j) Splenic and PDA-infiltrating iαβTs, CD4+ T cells, and CD8+ T cells were tested for expression of T-bet. (k) Splenic and orthotopic PDA-infiltrating iαβTs were tested for co-expression of IFNγ and IL-17A. (l) PDA-infiltrating CD3+IL-17+ cells were gated and tested for the frequency of CD4+ T cells, CD8+ T cells, NKT cells, γδT cells, and iαβTs. (m) Splenic and PDA-infiltrating iαβTs were cultured in vitro for 24h and cell culture supernatant was harvested and assayed for IL-17, IFNγ, and IL-10 (n=5/group). Flow cytometry experiments were repeated more than 4 times with similar results (n=5 mice for each replicate experiment; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).